Document:

EX-4.1

 Exhibit 4.1 

Explanatory Note: Due to adjustments resulting from the transactions contemplated by the Agreement and Plan of Merger and Reorganization, dated as of August
8, 2017, by and between Melinta Therapeutics, Inc. (f/k/a Cempra, Inc.), Castle Acquisition Corp. and Melinta Subsidiary Corp. (f/k/a Melinta Therapeutics, Inc.), which were consummated on November 3, 2017, the below warrant is for a total of 44,583
shares of common stock at a purchase price of $33.30. 
 THIS WARRANT, AND THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT, HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ ACT”), OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, TRANSFERRED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT, OR ANY APPLICABLE STATE SECURITIES LAWS. 

WARRANT AGREEMENT 
 To
Purchase Shares of Preferred Stock of  
 MELINTA THERAPEUTICS, INC. 

Dated as of December 17, 2014 (the “Effective Date”) 

WHEREAS, Melinta Therapeutics, Inc., a Delaware corporation (as more fully defined below, the “Company”), has entered into a Loan and
Security Agreement of even date herewith (as modified, amended and/or restated and in effect from time to time, the “Loan Agreement”) with Hercules Technology Growth Capital, Inc., a Maryland corporation, in its capacity as
administrative agent for itself and the Lender (as defined in the Loan Agreement) (the “Warrantholder”); 
 WHEREAS, the Company desires to
grant to Warrantholder, in consideration for, among other things, the financial accommodations provided for in the Loan Agreement, the right to purchase shares of Preferred Stock (as defined below) pursuant to this Warrant Agreement (this
“Warrant” or this “Agreement”); 
 NOW, THEREFORE, in consideration of the Warrantholder executing and delivering the Loan
Agreement and providing the financial accommodations contemplated therein, and in consideration of the mutual covenants and agreements contained herein, the Company and Warrantholder agree as follows: 

SECTION 1. GRANT OF THE RIGHT TO PURCHASE PREFERRED STOCK. 

(a) For value received, the Company hereby grants to the Warrantholder the right to subscribe for and purchase from the Company, at any time
and from time to time on or before the Expiration Date (as defined below), up to such number of fully paid and non-assessable shares of Preferred Stock as determined pursuant to Section 1(b) below, at a
purchase price per share equal to the Exercise Price (as defined below). As used herein, the following terms shall have the following meanings: 

“Act” means the Securities Act of 1933, as amended. 

“Company” means Melinta Therapeutics, Inc., a Delaware corporation, and any successor corporation. 

“Charter” means the Company’s Certificate of Incorporation or other constitutional document, as may be amended and/or
restated and in effect from time to time. 
 “Common Stock” means the Company’s common stock, $0.001 par value per
share, and any other class, series or other designation of security into or for which such common stock is converted, substituted or exchanged pursuant to a reorganization, reclassification, recapitalization or similar transaction. 

“Discounted IPO Price” means eighty percent (80%) of the price to the public per share of Common Stock offered in the Initial
Public Offering as set forth in the Company’s final prospectus filed with the U.S. Securities and Exchange Commission in connection therewith pursuant to Rule 424(b) promulgated under the Act. 

 “Excluded Issuance” means any issuance or sale by the Company after the Effective Date
of (i) shares of Preferred Stock issued upon exercise of this Agreement or (ii) securities covered by Section 4.3(e) of the Securityholders Agreement in effect as of the Effective Date. 

“Exercise Price” means $0.976616 per share, subject to adjustment from time to time in accordance with the provisions of this
Warrant; provided, that if the Next Preferred Round Price shall be lower than the then-effective Exercise Price, then “Exercise Price” shall mean the Next Preferred Round Price from and after the closing of the Next Preferred Round,
subject to adjustment thereafter from time to time in accordance with the provisions of this Warrant; provided further, that if the Discounted IPO Price is less than the Exercise Price that would otherwise be in effect hereunder as of
immediately following the consummation of the Initial Public Offering, then, assuming this Warrant has not been exercised in full prior to the consummation of the Initial Public Offering, “Exercise Price” shall mean the Discounted IPO
Price from and after the consummation of the Initial Public Offering, subject to adjustment thereafter from time to time in accordance with the provisions of this Warrant. 

“Merger Event” means any transaction or series of related transactions involving: (i) the sale, lease, exclusive license,
or other disposition of all or substantially all of the assets of the Company, (ii) the merger or consolidation of the Company into or with another person or entity (other than a merger or consolidation effected exclusively to change the
Company’s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such immediately prior to such merger, consolidation or reorganization, own less than a majority of the Company’s (or
the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation or reorganization (or, if such Company stockholders beneficially own a majority of the outstanding voting power of the surviving or
successor entity as of immediately after such merger, consolidation or reorganization, such surviving or successor entity is not the Company); or (iii) any sale or other transfer by the stockholders of the Company of shares representing at
least a majority of the Company’s then-total outstanding combined voting power. 
 “Next Preferred Round” means the
first offering and sale by the Company, on or after the Effective Date, of shares of its convertible preferred stock (or of promissory notes or other similar instruments or rights convertible into or exchangeable or exercisable for a class and/or
series of convertible preferred stock, whether or not then established by the Company in the Charter), to one or more investors for cash for financing purposes (other than an Excluded Issuance),, in a single transaction or series of related
transactions not registered under the Act, resulting in aggregate gross cash proceeds received by the Company of at least $1,000,000; provided, that Next Preferred Round shall not include any additional sales of Series 3 Stock by the Company.

 “Next Preferred Round Price” means the lowest effective price per share for which shares of the Next Round Preferred
Series are sold and issued in the Next Preferred Round (including, without limitation, issuances pursuant to the conversion, exchange or exercise of promissory notes or other similar instruments or rights to acquire shares of the Next Round
Preferred Series following the Company’s original sale and issuance of such promissory notes, instruments and/or rights). 

“Next Preferred Round Series” means the class, series and/or other designation of the shares of convertible preferred stock
sold and issued by the Company in the Next Preferred Round (including, without limitation, issuances pursuant to the conversion, exchange or exercise of promissory notes or other similar instruments or rights to acquire shares of the Next Round
Preferred Series following the Company’s original sale and issuance of such promissory notes, instruments and/or rights), and any other class, series or other designation of security into or for which such Next Preferred Round Series is
converted, substituted or exchanged pursuant to a reorganization, reclassification, recapitalization or similar transaction. 

“Preferred Stock” means Series 3 Stock; provided, that if the Next Preferred Round Price shall be lower than the
then-effective Exercise Price, then “Preferred Stock” shall mean the Next Preferred Round Series from and after the closing of the Next Preferred Round; provided, further, that, upon and after the occurrence of an event which
results in the automatic or voluntary conversion, redemption or retirement of all (but not less than all) of the outstanding shares of such Preferred 

  
 2 

 
Stock pursuant to the consummation of an Initial Public Offering, then from and after the date upon which such outstanding shares are so converted, redeemed or retired, “Preferred
Stock” shall mean the Common Stock. 
 “Purchase Price” means, with respect to any exercise of this Agreement, an
amount equal to the Exercise Price as of the relevant time multiplied by the number of shares of Preferred Stock requested to be exercised under this Agreement pursuant to such exercise. 

“Rights Agreement” means that certain Fifth Amended and Restated Registration Rights Agreement, dated January 23, 2014, by and
among the Company and the securityholders identified therein, as may be amended and/or restated and in effect from time to time. 

“Securityholders Agreement” means that certain Seventh Amended and Restated Securityholders Agreement, dated January 23, 2014,
by and among the Company and the securityholders identified therein, as may be amended and/or restated and in effect from time to time. 

“Series 3 Stock” means the Company’s Series 3 Convertible Preferred Stock, $0.001 par value per share, as presently
constituted under the Charter, and any other class, series or other designation of security into or for which such Series 3 Convertible Preferred Stock is converted, substituted or exchanged pursuant to a reorganization, reclassification,
recapitalization or similar transaction. 
 (b) Number of Shares. This Warrant shall be exercisable for 1,151,936 shares of Preferred
Stock, subject to adjustment from time to time in accordance with the provisions of this Warrant (the “Initial Shares”); provided, that, in addition to and not in lieu of the Initial Shares, on such date (if any) as a Second
Term Loan Advance (as defined in the Loan Agreement) shall first be made to the Company in any amount during the Draw Period (as defined in the Loan Agreement), this Warrant automatically shall become exercisable for a number of additional shares of
Preferred Stock as shall equal (i) $225,000, divided by (ii) the Exercise Price in effect on and as of such date, subject to further adjustment thereafter from time to time in accordance with the provisions of this Warrant. 

SECTION 2. TERM OF THE AGREEMENT. 

Except as otherwise provided for herein, the term of this Agreement and the right to purchase Preferred Stock as granted herein shall commence on the
Effective Date and shall be exercisable for a period ending upon the tenth (10th) anniversary of the Effective Date (the “Expiration Date”). 

SECTION 3. EXERCISE OF THE PURCHASE RIGHTS. 

(a) Exercise. The purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at any time,
or from time to time, prior to the expiration of the term set forth in Section 2 or earlier termination of this Agreement, by tendering to the Company at its principal office a notice of exercise in the form attached hereto as Exhibit I
(the “Notice of Exercise”), duly completed and executed and payment in full of the Purchase Price in accordance with the terms set forth below. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in
accordance with the terms set forth below, and in no event later than three (3) business days thereafter, the Company shall issue to the Warrantholder a certificate for the number of shares of Preferred Stock purchased and shall execute the
acknowledgment of exercise in the form attached hereto as Exhibit II (the “Acknowledgment of Exercise”) indicating the number of shares which remain subject to future purchases, if any. 

The Purchase Price may be paid at the Warrantholder’s election either (i) by cash or check, or (ii) by surrender of all or a portion of the
Warrant for shares of Preferred Stock to be exercised under this Agreement and, if applicable, an amended Agreement representing the remaining number of shares purchasable hereunder, as determined below (“Net Issuance”). If the
Warrantholder elects the Net Issuance method, the Company will issue Preferred Stock in accordance with the following formula: 

  
 3 

					
		  		  	 X = Y(A-B)

A

	Where:	  	X =	  	the number of shares of Preferred Stock to be issued to the Warrantholder.
			
		  	Y =	  	the number of shares of Preferred Stock requested to be exercised under this Agreement.
			
		  	A =	  	the fair market value of one (1) share of Preferred Stock at the time of issuance of such shares of Preferred Stock.
			
		  	B =	  	the Exercise Price.

 For purposes of the above calculation, current fair market value of Preferred Stock shall mean with respect to each share of
Preferred Stock: 
 (i) if the exercise is in connection with an Initial Public Offering, and if the Company’s
Registration Statement relating to such Initial Public Offering has been declared effective by the U.S. Securities and Exchange Commission, then the fair market value per share shall be the product of (x) the initial “Price to Public”
of the Common Stock specified in the final prospectus with respect to the offering and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise; 

(ii) if the exercise is after, and not in connection with an Initial Public Offering, and: 

(A) if the Common Stock is traded on a securities exchange, the fair market value shall be deemed to be the product of
(x) the average of the closing prices over the five (5) period before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Preferred Stock is
convertible at the time of such exercise (provided that if the Preferred Stock is Common Stock, clause (y) shall equal one); or 

(B) if the Common Stock is traded
over-the-counter, the fair market value shall be deemed to be the product of (x) the average of the closing bid and asked prices quoted on the NASDAQ system (or
similar system) over the five (5) period before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of
such exercise (provided that if the Preferred Stock is Common Stock, clause (y) shall equal one); 
 (iii) if at any
time the Common Stock is not listed on any securities exchange or quoted in the NASDAQ National Market or the over-the-counter market, the current fair market value of
Preferred Stock shall be the fair market value as determined in good faith by its Board of Directors, unless the Company shall become subject to a Merger Event, in which case the fair market value of Preferred Stock shall be deemed to be the per
share value received by the holders of the Company’s Preferred Stock on a common equivalent basis pursuant to such Merger Event. 
 Upon partial
exercise by either cash or Net Issuance, the Company shall promptly issue an amended Agreement representing the remaining number of shares purchasable hereunder. All other terms and conditions of such amended Agreement shall be identical to those
contained herein, including, but not limited to the Effective Date hereof. 

  
 4 

 (b) Exercise Prior to Expiration. To the extent this Agreement is not previously exercised
as to all Preferred Stock subject hereto, and if the fair market value (as determined pursuant to Section 3(a)) of one share of the Preferred Stock is greater than the Exercise Price then in effect, this Agreement shall be deemed automatically
exercised pursuant to Section 3(a) (even if not surrendered) immediately before its expiration. For purposes of such automatic exercise, the fair market value of one share of the Preferred Stock upon such expiration shall be determined pursuant
to Section 3(a). To the extent this Agreement or any portion thereof is deemed automatically exercised pursuant to this Section 3(b), the Company agrees to promptly notify the Warrantholder of the number of shares of Preferred Stock, if
any, the Warrantholder is to receive by reason of such automatic exercise. 
 SECTION 4. RESERVATION OF SHARES. 

During the term of this Agreement, the Company will at all times have authorized and reserved a sufficient number of shares of its Preferred Stock to provide
for the exercise of the rights to purchase Preferred Stock as provided for herein, and shall have authorized and reserved a sufficient number of shares of its Common Stock to provide for the conversion of the shares of Preferred Stock issuable
hereunder. 
 SECTION 5. NO FRACTIONAL SHARES OR SCRIP. 

No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Agreement, but in lieu of such fractional shares the
Company shall make a cash payment therefor upon the basis of the then-fair market value of one share of Preferred Stock. 
 SECTION
6. NO RIGHTS AS STOCKHOLDER. 
 This Agreement does not entitle the Warrantholder to any voting rights or other rights as a stockholder of the
Company prior to the exercise of this Agreement. 
 SECTION 7. WARRANTHOLDER REGISTRY. 

The Company shall maintain a registry showing the name and address of the registered holder of this Agreement. Warrantholder’s initial address, for
purposes of such registry, is set forth below Warrantholder’s signature on this Agreement. Warrantholder may change such address by giving written notice of such changed address to the Company. 

SECTION 8. ADJUSTMENT RIGHTS. 

The Exercise Price and the number of shares of Preferred Stock purchasable hereunder are subject to adjustment, as follows: 

(a) Merger Event. If at any time there shall be Merger Event, then, as a part of such Merger Event, lawful provision shall be made so
that the Warrantholder shall thereafter be entitled to receive, upon exercise of this Agreement, the number of shares of preferred stock or other securities or property (collectively, “Reference Property”) that the Warrantholder
would have received in connection with such Merger Event if Warrantholder had exercised this Agreement immediately prior to the Merger Event. In any such case, appropriate adjustment (as determined in good faith by the Company’s Board of
Directors) shall be made in the application of the provisions of this Agreement with respect to the rights and interests of the Warrantholder after the Merger Event to the end that the provisions of this Agreement (including adjustments of the
Exercise Price and adjustments to ensure that the provisions of this Section 8 shall thereafter be applicable, as nearly as possible, to the purchase rights under this Agreement in relation to any Reference Property thereafter acquirable upon
exercise of such purchase rights) shall continue to be applicable in their entirety, and to the greatest extent possible. Without limiting the foregoing, in connection with any Merger Event, upon the closing thereof, the successor or surviving
entity shall assume the obligations of this Agreement; provided, that the foregoing assumption requirement shall not apply if the consideration to be paid for or in respect of the outstanding shares of Preferred Stock in such Merger Event
consists solely of cash and/or readily Marketable Securities, which, for the avoidance of doubt, includes any right to receive cash and/or Marketable Securities following the closing of such Merger Event pursuant to an escrow, earn-out, milestone, royalty or other similar arrangement. “Marketable Securities” means securities that are freely traded on The OTC Bulletin Board, The NASDAQ Global Market, The NASDAQ Global Select
Market, The NASDAQ Capital Market, the New York Stock Exchange, NYSE 

  
 5 

 
Area, the NYSE MKT, or the OTCQX Marketplace or the OTCQB Marketplace operated by OTC Markets Group Inc. (or any successor to any of the foregoing) or any other similar exchanges worldwide.
Marketable Securities shall include any such securities issued in a Merger Event regardless of whether such securities are subject to a lock-up agreement, provided that any such
lock-up agreement applicable to the Warrantholder shall only be on the same terms as (or more favorable to the Warrantholder) and no more restrictive than the lock-up
agreed to and in full force effect with respect to all holders of Preferred Stock and by all executive officers, directors and holders of at least three (3%) of the outstanding equity securities of the Company (any waiver of such lock-up for any of the foregoing shall automatically result in a waiver of the same for the Warrantholder); and the Company shall confirm the same in writing to the Warrantholder as of the date of the Merger Event.
In connection with a Merger Event and upon Warrantholder’s written election to the Company, the Company shall cause this Warrant Agreement to be exchanged for the consideration that Warrantholder would have received if Warrantholder had chosen
to exercise its right to have shares issued pursuant to the Net Issuance provisions of this Warrant Agreement without actually exercising such right, acquiring such shares and exchanging such shares for such consideration. The provisions of this
Section 8(a) shall similarly apply to successive Merger Events. 
 (b) Reclassification of Shares. Except for Merger Events
subject to Section 8(a), if the Company at any time shall, by combination, reclassification, reorganization, exchange or subdivision of securities or otherwise, change any of the securities as to which purchase rights under this Agreement exist
into the same or a different number of securities of any other class or classes, this Agreement shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect
to the securities which were subject to the purchase rights under this Agreement immediately prior to such combination, reclassification, exchange, subdivision or other change. The provisions of this Section 8(b) shall similarly apply to
successive combination, reclassification, exchange, subdivision or other change. 
 (c) Subdivision or Combination of Shares. If the
Company at any time shall combine or subdivide its Preferred Stock, (i) in the case of a subdivision, the Exercise Price shall be proportionately decreased and the number of shares of Preferred Stock purchasable hereunder shall be
proportionately increased, or (ii) in the case of a combination, the Exercise Price shall be proportionately increased and the number of shares of Preferred Stock purchasable hereunder shall be proportionately decreased. 

(d) Stock Dividends. If the Company at any time while this Agreement is outstanding and unexpired shall: 

(i) pay a dividend with respect to the Preferred Stock payable in Preferred Stock, then the Exercise Price shall be adjusted,
from and after the date of determination of stockholders entitled to receive such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of determination by a fraction
(A) the numerator of which shall be the total number of shares of Preferred Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of Preferred Stock
outstanding immediately after such dividend or distribution; or 
 (ii) make any other distribution with respect to Preferred
Stock (or stock into which the Preferred Stock is convertible), except (x) any distribution specifically provided for in any other clause of this Section 8, and (y) any accruing dividends set forth in the Charter on the Preferred
Stock, then, in each such case, provision shall be made by the Company such that the Warrantholder shall receive upon exercise or conversion of this Warrant a proportionate share of any such distribution as though it were the holder of the Preferred
Stock (or other stock for which the Preferred Stock is convertible) as of the record date fixed for the determination of the stockholders of the Company entitled to receive such distribution. 

  
 6 

 (e) Antidilution Rights. Additional antidilution rights applicable to the Preferred Stock
purchasable hereunder are as set forth in the Charter and shall be applicable with respect to the Preferred Stock issuable hereunder. The Company shall promptly provide the Warrantholder with any restatement, amendment, modification or waiver of the
Charter; provided, that no such amendment, modification or waiver shall impair or reduce the antidilution rights applicable to the Preferred Stock unless such amendment, modification or waiver affects the rights of Warrantholder with respect
to the Preferred Stock in the same manner as it affects all other holders of Preferred Stock. The Company shall provide Warrantholder with written notice of any issuance of its stock or other equity security to occur after the Effective Date of this
Agreement, which notice shall include (a) the price at which such stock or security is sold, (b) the number of shares issued, and (c) such other information as necessary for Warrantholder to determine if a dilutive event has occurred;
provided that failure to provide such notice shall not constitute a breach of this Warrant unless Warrantholder is materially prejudiced thereby. For the avoidance of doubt, there shall be no duplicate anti-dilution adjustment pursuant to this
subsection (e), the forgoing subsection (d) and the Charter.. 
 (f) [Intentionally Omitted] 

(g) Notice of Adjustments. If: (i) the Company shall declare or pay any dividend or distribution upon the outstanding shares of
Preferred Stock (or Common Stock if shares of Preferred Stock are then convertible into Common Stock) whether in stock, cash, or other property; (ii) the Company shall offer for subscription pro rata to the holders of the Preferred Stock or
other capital stock any additional shares of stock of any class or other rights; (iii) there shall be any Merger Event; (iv) there shall be an Initial Public Offering; or (v) there shall be any voluntary or involuntary dissolution,
liquidation or winding up of the Company; then, in connection with each such event, the Company shall use reasonable best efforts to send to the Warrantholder: (A) at least fifteen (15) days’ (but in no event less than ten
(10) days’) prior written notice of the date on which the books of the Company shall close or a record shall be taken for such dividend, distribution, subscription rights (specifying the date on which the holders of Preferred Stock shall
be entitled thereto) or for determining rights to vote in respect of such Merger Event, dissolution, liquidation or winding up; (B) in the case of any such Merger Event, at least fifteen (15) days’ (but in no event less than ten
(10) days’) prior written notice of the date when the same shall take place (and specifying the date on which the holders of Preferred Stock shall be entitled to exchange their Preferred Stock for securities or other property deliverable
upon such Merger Event, dissolution, liquidation or winding up); and (C) in the case of an Initial Public Offering, at least fifteen (15) days’ (but in no event less than ten (10) days’) written notice prior to the
anticipated effective date thereof. Each such written notice shall set forth, in reasonable detail, (i) the event requiring the notice, and (ii) if any adjustment is required to be made, (A) the amount of such adjustment, (B) the
method by which such adjustment was calculated, (C) the adjusted Exercise Price (if the Exercise Price has been adjusted), and (D) the number of shares subject to purchase hereunder after giving effect to such adjustment, and shall be given in
accordance with Section 12(g) below. 
 (h) Timely Notice. Failure to timely provide such notice required by subsection (g)
above shall entitle Warrantholder to retain the benefit of the applicable notice period notwithstanding anything to the contrary contained in any insufficient notice received by Warrantholder. For purposes of this subsection (h), and notwithstanding
anything to the contrary in Section 12(g), the notice period shall begin on the date Warrantholder actually receives a written notice containing all the information required to be provided in such subsection (g). 

SECTION 9. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. 

(a) Reservation of Preferred Stock. The Preferred Stock issuable upon exercise of the Warrantholder’s rights has been or, in the
case of Preferred Stock issuable in the Next Preferred Round, will be, and all shares of Common Stock issuable upon conversion of such Preferred Stock at all times will be, duly and validly reserved and, when issued in accordance with the provisions
of this Agreement or the Charter, as applicable, will be validly issued, fully paid and non-assessable, and will be free of any taxes, liens, charges or encumbrances of any nature whatsoever other than
restrictions on transfer under state 

  
 7 

 
and/or federal securities laws. The Company has made available to the Warrantholder true, correct and complete copies of its Charter and current bylaws. The issuance of certificates for shares of
Preferred Stock upon exercise of this Agreement shall be made without charge to the Warrantholder for any issuance tax in respect thereof, or other cost incurred by the Company in connection with such exercise and the related issuance of shares of
Preferred Stock; provided, that the Company shall not be required to pay any tax which may be payable in respect of any transfer and the issuance and delivery of any certificate in a name other than that of the Warrantholder, and no such
issuance or delivery shall be made unless and until the person requesting such issuance has paid to the Company the amount of any such tax, or has established to the satisfaction of the Company that such tax has been paid. 

(b) Due Authority. The execution and delivery by the Company of this Agreement and the performance of all obligations of the Company
hereunder, including the issuance to Warrantholder of the right to acquire the shares of Preferred Stock and the Common Stock into which it may be converted, have been duly authorized by all necessary corporate action on the part of the Company.
This Agreement: (1) does not violate the Company’s Charter or current bylaws; (2) does not contravene any material law or governmental rule, regulation or order applicable to it; and (3) does not and will not contravene any
provision of, or constitute a default under, any indenture, mortgage, material contract or other material instrument to which it is a party or by which it is bound. This Agreement constitutes a legal, valid and binding agreement of the Company,
enforceable in accordance with its terms, subject to bankruptcy, insolvency, reorganization, moratorium, or other similar Laws affecting or relating to creditors’ rights generally, and the availability of injunctive relief and other equitable
remedies. 
 (c) Consents and Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other
action in respect of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and performance by the Company of its obligations under this Agreement, except, if applicable, for the filing of
notices pursuant to Regulation D under the Act (“Regulation D”) and any filing required by applicable state securities law, which filings will be effective by the time required thereby. 

(d) Issued Securities. All issued and outstanding shares of Common Stock, Preferred Stock or any other securities of the Company have
been duly authorized and validly issued and are fully paid and non-assessable. All outstanding shares of Common Stock, Preferred Stock and any other securities were issued in full compliance with all federal
and state securities laws. In addition, as of the date immediately preceding the date of this Agreement: 
 (i) The
authorized capital of the Company consists of (A) 210,000,000 shares of Common Stock, of which 68,866 shares are issued and outstanding, and (B)181,725,142 shares of Preferred Stock, of which 159,198,380 shares are issued and outstanding. 

(ii) The Company has reserved 27,165,274 shares of Common Stock for issuance under its Stock Option Plan(s), under which
22,309,765 options are outstanding. Except for options under the Stock Option Plan and the warrants set forth on Schedule 9, there are no other options, warrants, conversion privileges or other rights presently outstanding to purchase or
otherwise acquire any authorized but unissued shares of the Company’s capital stock or other securities of the Company. The Company has no outstanding loans to any employee, officer or director of the Company. 

(iii) Except as set forth in the Securityholders Agreement and in the Letter Agreement between the Company and Oxford Finance
LLC, dated February 17, 2012, no shareholder of the Company has preemptive rights to purchase new issuances of the Company’s capital stock. 

  
 8 

 (e) Registration Rights. The Company agrees that the shares of Common Stock issued and
issuable upon conversion of the shares of Preferred Stock issued and issuable upon exercise of this Warrant, and, at all times (if any) when the Preferred Stock shall be Common Stock, the shares of Preferred Stock issued and issuable upon exercise
of this Warrant, shall have the registration rights pursuant to and as set forth in the Rights Agreement on a pari passu basis with the holders of outstanding shares of Preferred Stock who are parties thereto. The provisions set forth in the
Rights Agreement or similar agreement relating to such registration rights in effect as of the Effective Date (other than provisions relating to demand registration rights) may not be amended, modified or waived without the prior written consent of
the Warrantholder unless such amendment, modification or waiver affects the rights associated with the shares of Preferred Stock issued and issuable upon exercise hereof in the same manner as such amendment, modification, or waiver affects the
rights associated with all outstanding shares of Preferred Stock whose holders are parties thereto. For the avoidance of doubt, the Warrantholder shall not be entitled to any demand registration rights under the Rights Agreement. 

(f) Other Commitments to Register Securities. Except as set forth in this Agreement and the Rights Agreement, the Company is not,
pursuant to the terms of any other agreement currently in existence, under any obligation to register under the Act any of its presently outstanding securities or any of its securities which may hereafter be issued. 

(g) Exempt Transaction. Subject to the accuracy of the Warrantholder’s representations in Section 10, the issuance of the
Preferred Stock upon exercise of this Agreement, and the issuance of the Common Stock upon conversion of the Preferred Stock, will each constitute a transaction exempt from (i) the registration requirements of Section 5 of the Act, in
reliance upon Section 4(2) thereof, and (ii) the qualification requirements of the applicable state securities laws. 
 (h)
Compliance with Rule 144. Following the Initial Public Offering or in the event the Company is publicly traded, if the Warrantholder proposes to sell Preferred Stock or Common Stock issuable upon the exercise of this Agreement in compliance
with Rule 144 promulgated by the SEC, then, upon Warrantholder’s written request to the Company, the Company shall furnish to the Warrantholder, within ten days after receipt of such request, a written statement confirming the Company’s
compliance with the filing requirements of the SEC as set forth in such Rule, as such Rule may be amended from time to time. 
 (i)
Information Rights. From the Effective Date until the date a registration statement is declared effective in connection with an Initial Public Offering, Warrantholder shall be entitled to the information rights contained in
Section 7.1(a)-(c) of the Loan Agreement, and Section 7.1(a)-(c) of the Loan Agreement is hereby incorporated into this Agreement by this reference as though fully set forth herein. 

SECTION 10. REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER. 

This Agreement has been entered into by the Company in reliance upon the following representations and covenants of the Warrantholder: 

(a) Investment Purpose. This Warrant is being acquired, and the Preferred Stock issuable upon exercise hereof will be acquired, for
investment for the Warrantholder’s own account and not with a view to the sale or distribution of any part thereof, and the Warrantholder has, and at the time of exercise will have, no present intention of selling or engaging in any public
distribution of the same except pursuant to an effective registration statement or an exemption from the registration requirements of the Act. 

(b) Private Issue. The Warrantholder understands (i) that the Preferred Stock issuable upon exercise of this Agreement is not
registered under the Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Agreement will be exempt from the registration and qualifications requirements thereof, and (ii) that the
Company’s reliance on such exemption is predicated on the representations set forth in this Section 10. 

  
 9 

 (c) Financial Risk. The Warrantholder has such knowledge and experience in financial and
business matters as to be capable of evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment. The Warrantholder has had an opportunity to ask questions and receive answers from the Company
regarding the terms and conditions of the offering of the Warrant and the business, properties, prospects and financial condition of the Company. 

(d) Risk of No Registration. The Warrantholder understands that if the Company does not register with the SEC pursuant to
Section 12 of the Securities Exchange Act of 1934 (the “1934 Act”), or file reports pursuant to Section 15(d) of the 1934 Act, or if a registration statement covering the securities under the Act is not in effect when it
desires to sell (i) the rights to purchase Preferred Stock pursuant to this Agreement or (ii) the Preferred Stock issuable upon exercise of the right to purchase, it may be required to hold such securities for an indefinite period. The
Warrantholder also understands that any sale of (A) its rights hereunder to purchase Preferred Stock or (B) Preferred Stock issued or issuable hereunder which might be made by it in reliance upon Rule 144 under the Act may be made only in
accordance with the terms and conditions of that Rule. 
 (e) Accredited Investor. Warrantholder is an “accredited
investor” within the meaning of the Securities and Exchange Rule 501 of Regulation D, as presently in effect. 
 (f)
Authorization. The Warrantholder has full power and authority to enter into this Agreement. This Agreement constitutes a legal, valid and binding agreement of the Warrantholder, enforceable in accordance with its terms, subject to bankruptcy,
insolvency, reorganization, moratorium, or other similar Laws affecting or relating to creditors’ rights generally, and the availability of injunctive relief and other equitable remedies. 

(g) Confidentiality. Warrantholder acknowledges that certain information and materials provided by the Company pursuant to its
obligations under this Warrant are confidential and proprietary information of the Company, and Warrantholder agrees to treat and hold such information in accordance with the confidentiality provisions set forth in Section 11.12 of the Loan
Agreement. 
 (h) Securityholders Agreement. 

(i) Notwithstanding anything to the contrary contained herein, if this Warrant is exercised in whole or in part during the term
of the Securityholders Agreement (including if this Warrant is exchanged for the consideration in a Merger Event pursuant to Section 8(a)), the Warrantholder shall automatically become a party to and bound by the Securityholders Agreement (and
upon the request of the Company the Warrantholder shall execute an instrument of accession to the Securityholders Agreement agreeing to be bound by and subject to the terms of the Securityholders Agreement) and shall be deemed to be a
“Securityholder” and “Series 3 Holder” (and shall have the rights of the same) (as revised, if necessary, to reflect the applicable series of Preferred Stock) thereunder. If this Warrant is exchanged for the consideration in a
Merger Event pursuant to Section 8(a), the Warrantholder shall be deemed automatically to become a party to and bound by the Securityholders Agreement immediately prior to the consummation of such Merger Event. The provisions of this
Section 10(h)(i) shall only be applicable if (a) all holders of outstanding shares of the Preferred Stock are then parties thereto, and (ii) the Securityholders Agreement is then by its terms in force and effect. 

  
 10 

 (ii) If at any time there shall be an Initial Public Offering, if this Warrant
has not been exercised by the Warrantholder prior to the consummation of such Initial Public Offering, the Warrantholder acknowledges and agrees to be bound by Section 8.8 (No Sale Period) of the Securityholders Agreement as if the
Warrantholder had become a party to the Securityholders Agreement. The provisions of this Section 10(h)(ii) shall only be applicable if (a) all holders of outstanding shares of the Preferred Stock are then parties to Section 8.8 (No
Sale Period) of the Securityholders Agreement, and (ii) Section 8.8 (No Sale Period) of the Securityholders Agreement is then by its terms in force and effect. 

SECTION 11. TRANSFERS. 
 Subject
to compliance with applicable federal and state securities laws, this Agreement and all rights hereunder are transferable, in whole or in part, without charge to the holder hereof (except for transfer taxes) upon surrender of this Agreement properly
endorsed; provided, that any transferee prior to the Initial Public Offering shall make the representations set forth in Section 10 and agrees, by acceptance of such transfer, to be bound by the covenants, terms and conditions of this
Warrant (in which event the transferee shall be deemed to be the Warrantholder for all purposes hereunder). Each taker and holder of this Agreement, by taking or holding the same, consents and agrees that this Agreement, when endorsed in blank,
shall be deemed negotiable, and that the holder hereof, when this Agreement shall have been so endorsed and its transfer recorded on the Company’s books, shall be treated by the Company and all other persons dealing with this Agreement as the
absolute owner hereof for any purpose and as the person entitled to exercise the rights represented by this Agreement. The transfer of this Agreement shall be recorded on the books of the Company upon receipt by the Company of a notice of transfer
in the form attached hereto as Exhibit III (the “Transfer Notice”), at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. Until the Company receives
such Transfer Notice, the Company may treat the registered owner hereof as the owner for all purposes. Notwithstanding the foregoing, prior to any proposed transfer of this Warrant, unless there is in effect a registration statement under the Act
covering the proposed transfer, Warrantholder shall give written notice to the Company of Warrantholder’s intention to effect such transfer. Each such notice shall describe the manner and circumstances of the proposed transfer in sufficient
detail, and shall, if the Company so requests, be accompanied by a customary written opinion of legal counsel who shall be reasonably satisfactory to the Company addressed to the Company and reasonably satisfactory in form and substance to
Company’s counsel, to the effect that the proposed transfer of this Warrant may be effected without registration under the Act and any applicable state securities laws, whereupon Warrantholder shall be entitled to transfer this Warrant in
accordance with the terms of the notice delivered by Warrantholder to the Company; provided, however, that the Company shall not require delivery of a legal opinion in connection with any assignment or transfer of this Warrant or any
shares of Preferred Stock issued on exercise hereof to an “affiliate” (as defined in Regulation D) of Warrantholder, provided that such affiliate transferee is an “accredited investor” (as defined in Regulation D).
Notwithstanding the foregoing, so long as no Event of Default (as defined and pursuant to the Loan Agreement) has occurred and is continuing, this Warrant shall not be transferable to any direct competitor of the Company prior to the Initial Public
Offering (as determined in good faith by the Board of Directors of the Company); provided that any entity (or any affiliate thereof) that is engaged in the pharmaceutical business shall be deemed to be a direct competitor of the Company).. 

SECTION 12. MISCELLANEOUS. 

(a) Effective Date. The provisions of this Agreement shall be construed and shall be given effect in all respects as if it had been
executed and delivered by the parties hereto on the date hereof. This Agreement shall be binding upon any successors or permitted assigns of the Company and any successors or assigns of the Warrantholder. 

  
 11 

 (b) Remedies. In the event of any default hereunder, the
non-defaulting party may proceed to protect and enforce its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or
an action for specific performance for any default where such party will not have an adequate remedy at law and where damages will not be readily ascertainable. Each party to this Agreement expressly agrees that it shall not oppose an application by
the other party or any other person entitled to the benefit of this Agreement requiring specific performance of any or all provisions hereof or enjoining the breaching party from continuing to commit any such breach of this Agreement. 

(c) Warrantholder acknowledges that certain items of information that may be provided to Warrantholder pursuant to Section 12(d) are
confidential and proprietary information of the Company, if and to the extent such information either (x) is marked as confidential by the Company at the time of disclosure, or (y) should reasonably be understood to be confidential (the
“Confidential Information”). Accordingly, Warrantholder agrees that any Confidential Information it may obtain pursuant to Section 12(d) shall not be disclosed to any other person or entity in any manner whatsoever, in whole or in
part, without the prior written consent of the Company, except that Warrantholder may disclose any such information: (a) to its own directors, officers, employees, accountants, counsel and other professional advisors and to its affiliates if
Warrantholder in its sole discretion determines that any such party should have access to such information in connection with Warrantholder’s evaluation of whether to exercise (in cash or a net issuance basis) this Warrant and, provided that
such recipient of such Confidential Information either (i) agrees to be bound by the confidentiality provisions of this paragraph or (ii) is otherwise subject to confidentiality restrictions that reasonably protect against the disclosure
of Confidential Information; (b) if such information is generally available to the public; (c) if required or appropriate in any report, statement or testimony submitted to any governmental authority having or claiming to have jurisdiction
over Warrantholder; (d) if required or appropriate in response to any summons or subpoena or in connection with any litigation, to the extent permitted or deemed advisable by Warrantholder’s counsel; (e) to comply with any legal
requirement or law applicable to Warrantholder; (f) to any transferee of Warrantholder permitted by and pursuant to Section 11 or any prospective transferee permitted by and pursuant to Section 11; provided, that such transferee or
prospective transferee agrees in writing to be bound by this Section prior to disclosure; or (g) otherwise with the prior consent of the Company; provided, that any disclosure made in violation of this Agreement shall not affect the obligations
of any party under this Agreement. 
 (d) Additional Documents. Upon Warrantholder’s written request, the Company shall supply
legal and financial documentation reasonably necessary to evaluate whether to exercise (in cash or a net issuance basis) this Warrant, including without limitation, (i) any merger/purchase/asset sale agreement and related documents and
estimated payout allocations to each of the respective shareholders, warrant and option holders in connection with a Merger Event, (ii) the most recent capitalization tables, 409A valuations (if any), and board determination of share value
(including any waterfall or per share allocations provided to the shareholders), and (iii) most recent Charter. 
 (e)
Attorneys’ Fees. In any litigation, arbitration or court proceeding between the Company and the Warrantholder relating hereto, the prevailing party shall be entitled to reasonable attorneys’ fees and expenses and all costs of
proceedings incurred in enforcing this Agreement. For the purposes of this Section 12(e), attorneys’ fees shall include without limitation reasonable fees incurred in connection with the following: (i) contempt proceedings;
(ii) discovery; (iii) any motion, proceeding or other activity of any kind in connection with an insolvency proceeding; (iv) garnishment, levy, and debtor and third party examinations; and (v) post-judgment motions and proceedings of
any kind, including without limitation any activity taken to collect or enforce any judgment. 
 (f) Severability. In the event any
one or more of the provisions of this Agreement shall for any reason be held invalid, illegal or unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by
a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the parties underlying the invalid, illegal or unenforceable provision. 

  
 12 

 (g) Notices. Except as otherwise provided herein, any notice, demand, request, consent,
approval, declaration, service of process or other communication that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served,
given, delivered, and received upon the earlier of: (i) the day of transmission by facsimile, e-mail or hand delivery if transmission or delivery occurs on a business day at or before 5:00 pm in the time
zone of the recipient, or, if transmission or delivery occurs on a non-business day or after such time, the first business day thereafter, or the first business day after deposit with an overnight express
service or overnight mail delivery service; or (ii) the third calendar day after deposit in the United States mails, with proper first class postage prepaid, and shall be addressed to the party to be notified as follows: 

If to Warrantholder: 
 HERCULES TECHNOLOGY GROWTH
CAPITAL, INC. 
 Legal Department 

Attention: Chief Legal Officer and Manuel Henriquez 

400 Hamilton Avenue, Suite 310 

Palo Alto, CA 94301 
 Facsimile: 650-473-9194 
 Telephone: 650-289-3060 
 E-mail: CFera@herculestech.com;
Arora@herculestech.com; and 
 legal@herculestech.com 

If to the Company: 
 Melinta Therapeutics, Inc.

 Attention: Chief Financial Officer 

300 George Street, Suite 301 
 New
Haven, Connecticut 06511 
 Telephone: 312-724-9407 (Paul
Estrem) 
      203-848-6262 (Agnes
Ryan) 
 E-mail: pestrem@melinta.com and Aryan@melinta.com 

or to such other address as each party may designate for itself by like notice. 

(h) Entire Agreement: Amendments. This Agreement constitutes the entire agreement and understanding of the parties hereto in respect of
the subject matter hereof, and supersedes and replaces in its entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof (including
Lender’s proposal letter dated November 6, 2014). None of the terms of this Agreement may be amended except by an instrument executed by each of the parties hereto. 

(i) Headings. The various headings in this Agreement are inserted for convenience only and shall not affect the meaning or
interpretation of this Agreement or any provisions hereof. 
 (j) No Strict Construction. The parties hereto have participated
jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof
shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement. 
 (k) No Waiver. No
omission or delay by any party at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by the other party at any time designated, shall be a waiver of any such right or
remedy to which such party is entitled, nor shall it in any way affect the right of such party to enforce such provisions thereafter. 

  
 13 

 (l) Survival. All agreements, representations and warranties contained in this Agreement,
and the agreements set forth in Sections 9(e) and 10(h) shall survive the execution and delivery of this Agreement and the expiration or other termination of this Agreement. 

(m) Governing Law. This Agreement has been negotiated and delivered to Warrantholder in the State of California, and shall have been
accepted by Warrantholder in the State of California. Delivery of Preferred Stock to Warrantholder by the Company under this Agreement is due in the State of California. This Agreement shall be governed by, and construed and enforced in accordance
with, the laws of the State of Delaware, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 

(n) Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Agreement may be brought in any
state or federal court of competent jurisdiction located in the State of Delaware. By execution and delivery of this Agreement, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in the State of Delaware;
(b) waives any objection as to jurisdiction or venue in the State of Delaware; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment
rendered thereby in connection with this Agreement. Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance with the requirements for notice set forth in
Section 12(g), and shall be deemed effective and received as set forth in Section 12(g). Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring
proceedings in the courts of any other jurisdiction. 
 (o) Mutual Waiver of Jury Trial. Because disputes arising in connection with
complex financial transactions are most quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be
resolved by a judge applying such applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM
(COLLECTIVELY, “CLAIMS”) ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR BY WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY. This waiver extends to all such Claims, including Claims that involve Persons other than the
Company and Warrantholder; Claims that arise out of or are in any way connected to the relationship between the Company and Warrantholder; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any
kind, arising out of this Agreement. 
 (p) [Intentionally omitted] 

(q) Prejudgment Relief. In the event Claims are to be resolved by arbitration, either party may seek from a court of competent
jurisdiction identified in Section 12(n), any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to
resolution by judicial reference. 
 (r) Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may
be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. 

[Remainder of Page Intentionally Left Blank] 

  
 14 

 IN WITNESS WHEREOF, the parties hereto have caused this Warrant Agreement to be executed by its officers
thereunto duly authorized as of the Effective Date. 
  

							
	 COMPANY:
	 		 	MELINTA THERAPEUTICS, INC.
				
		 		 	By:	 	/s/ Paul D. Estrem
		 		 	Name:	 	Paul D. Estrem
		 		 	Title:	 	CFO
			
	 WARRANTHOLDER:
	 		 	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
				
		 		 	By:	 	/s/ Ben Bang
		 		 	Name:	 	Ben Bang
		 		 	Title:	 	Associate General Counsel

  
 15 

 EXHIBIT I 

NOTICE OF EXERCISE 
 To:
[                                    ] 

 

	(1)	The undersigned Warrantholder hereby elects to purchase [            ] shares of the Series [      ] Preferred
Stock of [                        ], pursuant to the terms of the Agreement dated the
[      ] day of             , 2014 (the “Agreement”) between
[                        ] and the Warrantholder, and [CASH PAYMENT: tenders herewith payment of the Purchase Price in
full, together with all applicable transfer taxes, if any.] [NET ISSUANCE: elects pursuant to Section 3(a) of the Agreement to effect a Net Issuance.] 

  

	(2)	Please issue a certificate or certificates representing said shares of Series [      ] Preferred Stock in the name of the undersigned or in such other name as is specified below.

  

	
	
	 
	(Name)
	
	 
	(Address)

  

			
	WARRANTHOLDER:	 	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

 
			
	
		
	By:	 	 

 
			
	Name:	 	 

 
			
	Title:	 	 
	Date:	 	 

  
 16 

 EXHIBIT II 

ACKNOWLEDGMENT OF EXERCISE 
 The undersigned
[                                         
                   ], hereby acknowledge receipt of the “Notice of Exercise” from Hercules Technology Growth Capital, Inc., to purchase
[        ] shares of the Series [    ] Preferred Stock of
[                        ], pursuant to the terms of the Agreement, and further acknowledges that
[            ] shares remain subject to purchase under the terms of the Agreement. 
  

							
	 COMPANY:
	 		 	[                                    
                    ]

							
		 		 	  
    By:
	 	 

							
		 		 	     Title:	 	 

							
		 		 	     Date:	 	 

  
 17 

 EXHIBIT III 

TRANSFER NOTICE 
 (To transfer or assign the
foregoing Agreement execute this form and supply required information. Do not use this form to purchase shares.) 
 FOR VALUE RECEIVED, the foregoing
Agreement and all rights evidenced thereby are hereby transferred and assigned to 
  

					
	 	  	
	(Please Print)	  		  	
			
	whose address is	  	 	  	
	 	  	

  

			
		
	Dated:	 	 

 
			
	Holder’s Signature:	 	 

 
			
	Holder’s Address:	 	 
	 

 Signature Guaranteed:
                                         
                                         
                           

NOTE: The signature to this Transfer Notice must correspond with the name as it appears on the face of the Agreement, without alteration or enlargement or any
change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Agreement. 

  
 18EX-10.1

 Exhibit 10.1 

AMENDMENT NO. 1 TO THE 

CEMPRA, INC. 
 2011 EQUITY
INCENTIVE PLAN 
 This Amendment No. 1 (this “Amendment”) to the Cempra, Inc. 2011 Equity Incentive Plan, as
amended from time to time (the “Plan”), is made effective as of March 9, 2018. 
 WHEREAS, on November 3,
2017, Cempra, Inc., a Delaware corporation (the “Company”), completed its business combination with Melinta Therapeutics, Inc., a privately held Delaware corporation dedicated to the development and commercialization of novel
antibiotics (“Melinta”), in accordance with the terms of an Agreement and Plan of Merger and Reorganization, dated as of August 8, 2017, as amended on each of September 6, 2017 and October 24, 2017 (as so amended, the
“Merger Agreement”) by and among the Company, Melinta and Castle Acquisition Corp., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”); 

WHEREAS, on November 3, 2017, pursuant to the Merger Agreement, Merger Sub merged with and into Melinta, with Melinta surviving
the merger and becoming a wholly owned subsidiary of the Company (the “Merger”); 
 WHEREAS, concurrently with the
effectiveness of the Merger, the Company changed its name to Melinta Therapeutics, Inc. and Melinta changed its name to Melinta Subsidiary Corp.; 

WHEREAS, pursuant to Section 2(b)(vii) of the Plan, the Compensation Committee of the Company’s Board of Directors (the
“Committee”) may, at any time and from time to time, amend the Plan; and 
 WHEREAS, the Committee desires to amend
the name of the Plan to reflect the change to the Company’s name to Melinta Therapeutics, Inc. 
 NOW, THEREFORE, the Plan is
hereby amended, as follows: 
 1. Capitalized Terms. Capitalized terms that are not defined in this Amendment shall have
the meanings ascribed thereto in the Plan. 
 2. Amendment to the Plan. The name of the Plan and all references thereto
in the Plan are hereby amended and restated in their entirety from the “Cempra, Inc. 2011 Equity Incentive Plan” to the “Melinta Therapeutics, Inc. 2011 Equity Incentive Plan.” 

3. Ratification and Confirmation. Except as specifically amended by this Amendment, the Plan is hereby ratified and
confirmed in all respects and remains valid and in full force and effect. Whenever the Plan is referred to in this Amendment or in any other agreement, document or instrument, such reference shall be deemed to be to the Plan, as amended by this
Amendment, whether or not specific reference is made to this Amendment. 
 4. Governing Law. This Amendment shall be
governed by, and construed in accordance with, the laws of the State of Delaware, without reference to the principles of conflicts of laws thereof. 

5. Headings. Section headings are for convenience only and shall not be considered a part of this Amendment. 

*         *         *

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}]]